miRagen Therapeutics completes merger with Signal Genetics, raises $40.7M in equity financing

miRagen Therapeutics completes merger with Signal Genetics, raises $40.7M in equity financing

BOULDER -- Miragen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, announced its merger with... Read More

Monday February 20, 2017 0 comments Tags: Boulder, miRagen Therapeutics, Signal Genetics, William S. Marshall

MiRagen Therapeutics, Signal Genetics sign merger agreement

MiRagen Therapeutics, Signal Genetics sign merger agreement

BOULDER --Miragen Therapeutics and California-based Signal Genetics, Inc. (Nasdaq: SGNL) today announced they have entered into a definitive merger agreement in which the stockholders of miRagen... Read More

Tuesday November 1, 2016 0 comments Tags: miRagen Therapeutics, Signal Genetics, William S. Marshall, Samuel D. Riccitelli